Management of prostate cancer (PC) might be improved by combining external beam
radiotherapy (EBRT) and prostate-specific membrane antigen (PSMA)-targeted radioligand …

Clinical 177Lu-PSMA-617 radioligand therapy (RLT) is applied in advanced-stage prostate
cancer. However, to the best of our knowledge murine models to study the biologic effects of …

Introduction The prostate-specific membrane antigen (PSMA) targeted radioligand therapy
(PRLT) for the treatment of metastatic castration-resistant prostate cancer (mCRPC) patients …

Lu-177-based, targeted radiotherapeutics/endoradiotherapies are an emerging clinical tool
for the management of various cancers. The chelator 1, 4, 7, 10-tetraazacyclododecane-1, 4 …

Possibilities to improve the therapeutic efficacy of Lu-177–PSMA-617 radionuclide therapy
by modulation of target expression are being investigated. Knowledge on regulatory factors …

Purpose The prostate-specific membrane antigen (PSMA) has emerged as an interesting
target for radionuclide therapy of metastasized castration-resistant prostate cancer …

Purpose Various radiolabeled prostate-specific membrane antigen (PSMA)–targeting
tracers are clinically applied for prostate cancer (PCa) imaging and targeted radionuclide …

Background Prostate cancer patients with locoregional lymph node disease at diagnosis
(N1M0) still have a limited prognosis despite the improvements provided by aggressive …

The prostate-specific membrane antigen (PSMA)–targeted radiohybrid (rh) ligand [177Lu]
Lu-rhPSMA-7.3 has recently been assessed in a pretherapeutic dosimetry study on prostate …

Clinical trials have shown the significant efficacy of [177Lu] Lu-PSMA-617 for treating
prostate cancer. However, the pharmacokinetic characteristics and therapeutic performance …